-+ 0.00%
-+ 0.00%
-+ 0.00%
Orchestra BioMed Reports BACKBEAT Trial Fully Enrolled With 349 Patients
Share
Listen to the news
Orchestra BioMed Reports BACKBEAT Trial Fully Enrolled With 349 Patients
  • Orchestra BioMed outlined funding through 2028 at Lotte New York Palace, with $80.5 million in net public offering proceeds.
  • BACKBEAT completed enrollment with 349 patients randomized; primary endpoint data are due in the second quarter of 2027.
  • The FDA confirmed a PMA supplement pathway for AVIM Therapy; Medtronic will submit following the primary data presentation.
  • Potential FDA approval and a US commercial launch of AVIM Therapy are targeted for the first half of 2028.
  • Virtue trial enrollment is accelerating, with completion targeted by year-end 2027; 12-month primary endpoint follow-up could conclude in the second half of 2028.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Orchestra Biomed Holdings Inc. published the original content used to generate this news brief on November 17, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending